USC’s Keck Medicine is conducting a new research to see if immunotherapy administered at home is equally effective as in a hospital. The treatment goal of...
The immunotherapy drug, durvalumab, has been the norm of care for patients with stage III non-little cell lung cancer(NSCLC) to further develop endurance, when recommended after...
According to research that was published by Evernorth Research Institute1, novel immunotherapies hold promise for certain patient groups, but their clinical use remains suboptimal. For instance,...
